Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT01352273
NCT01352273CompletedPhase 1

A Phase Ib Open-label Dose Escalation Study of MEK162 and RAF265 in Adult Patients With Advanced Solid Tumors Harboring RAS or BRAFV600E Mutations

Array Biopharma, now a wholly owned subsidiary of Pfizer4 sites in 2 countries69 target enrollmentStarted: June 2011Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Phase 1
Status
Completed
Sponsor
Enrollment
69
Locations
4
Primary Endpoint
Incidence of Dose Limiting Toxicities
Study OverviewStudy DesignEligibility CriteriaArms & InterventionsOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

This is a multi- center, open-label, dose finding, Phase Ib study to be conducted in two stages: a dose escalation part to determine the maximum tolerated dose (MTD) safety and tolerability of concurrent administration of MEK162 and RAF265, followed by an expansion part to further assess the safety and preliminary anti-tumor efficacy of this oral combination within two separate patient populations: i) patients with advanced solid tumors harboring BRAFV600E mutations or ii) patients with advanced solid tumors harboring RAS mutations.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Patients with histologically or cytologically confirmed and non-resectable advanced solid tumors for which no further effective standard therapy exists.
  • •The patients' tumors must contain documented activating somatic BRAFV600E* , NRAS or KRAS mutations (except for pancreatic cancer)
  • •All patients enrolled MUST provide fresh or archival tumor samples at baseline to enable central confirmation of BRAF or KRAS/NRAS mutations
  • •Measurable, or non-measurable but evaluable disease as determined by RECIST
  • •Adequate bone marrow function
  • •Adequate hepatic and renal function
  • •Adequate cardiovascular function
  • •Negative serum β HCG test (female patients of childbearing potential only) within 72 hrs prior to first dose

Exclusion Criteria

  • •Patients with a history of primary central nervous system tumors or brain metastases or who have signs/symptoms attributable to brain metastases and have not been assessed with radiologic imaging to rule out the presence of brain metastases
  • •Current evidence of retinal disease; or ophthalmopathy as assessed by ophthalmologic examination at baseline that would be considered a risk factor for CSR/RVO (e.g., optic disc cupping, visual field defects, IOP > 21 mm Hg)
  • •Impaired cardio-/vascular function or clinically significant cardiovascular diseases, including any of the following:
  • •History/evidence of acute coronary syndromes (including MI, unstable angina, CABG, coronary angioplasty, or stenting) ≤ 6 months prior to starting study drugs
  • •Thromboembolic event (DVT, CVA, PE) ≤ 6 months prior to starting study
  • •Symptomatic CHF, history or current evidence of clinically significant cardiac arrhythmia and/or conduction abnormality
  • •Uncontrolled arterial hypertension, defined as BP > 140/100 mmHg (average of 3 consecutive readings)
  • •History of melena, hematemesis or hemoptysis within the last 3 months
  • •Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (> 5 mIU/mL)
  • •Other protocol-defined inclusion/exclusion criteria may apply

Arms & Interventions

MEK162 + RAF265

Experimental

Intervention: MEK162 + RAF265 (Drug)

Outcomes

Primary Outcomes

Incidence of Dose Limiting Toxicities

Time Frame: during the first 28 days of treatment with RAF265 and MEK162

Secondary Outcomes

  • Number of participants with adverse events and serious adverse events(18 months)
  • Tumor skin and blood samples will be collected before and during treatment with RAF265 and MEK162 to assess the combination's effects on the RAF/MEK/MAPK pathway with the clinical outcomes(18 months)
  • Time versus plasma concentration profiles of RAF265 and MEK162(10 months)
  • assess preliminary anti-tumor activity of the combination(every 8 weeks of treatment)

Investigators

Sponsor
Array Biopharma, now a wholly owned subsidiary of Pfizer
Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (4)

Loading locations...

Similar Trials

Completed
Phase 2
Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory LeukemiasCancer
NCT00920140GlaxoSmithKline97
Completed
Phase 1
Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of Selicrelumab (RO7009789) With Vanucizumab or Bevacizumab in Participants With Metastatic Solid TumorsAdvanced/Metastatic Solid Tumors
NCT02665416Hoffmann-La Roche94
Completed
Phase 1
A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid TumorsSolid Tumors Harboring a BRAF V600 Mutation
NCT01543698Pfizer189
Completed
Phase 1
A Dose-finding Study of Dalotuzumab in Subjects With Advanced Solid Tumors (MK-0646-002)Advanced Solid Tumors
NCT00635778Merck Sharp & Dohme LLC50
Completed
Phase 1
A Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast CancerMetastatic Breast Cancer
NCT00951665Genentech, Inc.107
MEK162 and RAF265 in Adult Patients With... | Clinical Trial